

**UTILITY
PATENT APPLICATION
TRANSMITTAL**
(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	674582-2001
First Inventor	DAVIDS ET AL.
Title	CYTOKINE ANTAGONIST MOLECULES
Express Mail Label No.	EV345012744US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: **Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**


17497 U.S.P.T.O.
10/17/06 9:11
111203

1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)
2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>
3. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i>	a. <input type="checkbox"/> Computer Readable Form (CFR)
- Descriptive title of the invention	b. <input type="checkbox"/> Specification sequence Listing on:
- Cross References to Related Applications	i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or
- Statement Regarding Fed sponsored R & D	ii. <input type="checkbox"/> paper
- Reference to sequence listing, a table, or a computer program listing appendix.	c. <input type="checkbox"/> Statements verifying identity of above copies
- Background of the Invention	
- Brief Summary of the Invention	
- Brief Description of the Drawings (<i>if filed</i>)	
- Detailed Description	
- Claim(s)	
- Abstract of the Disclosure	
4. <input checked="" type="checkbox"/> Drawing(s)(35 U.S.C. 113) [Total Sheets 22]	
5. Oath or Declaration [Total Pages 3]	
a. <input checked="" type="checkbox"/> Unexecuted	9. <input type="checkbox"/> Assignment Papers (cover sheet & documents(s))
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i>	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement Power of Attorney <i>(when there is an assignee)</i>
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	<input type="checkbox"/> Power of Attorney
11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)	
6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.	12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations (1)
13. <input type="checkbox"/> Preliminary Amendment	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:	14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>
<input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP)	15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
Prior application information:	16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach from PTO/SB/35 or its equivalent.
Examiner: _____	17. <input type="checkbox"/> Other: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Customer Number	20999	or <input type="checkbox"/> Correspondence address below	
Name	FROMMER LAWRENCE & HAUG LLP		
Address	745 Fifth Avenue		
City	NEW YORK	State	NEW YORK
Country	USA	Telephone	212-588-0800
Name (Print/Type)	Thomas J. Kowalski Angela M. Nigro	Registration No. (Attorney/Agent)	32,147 51,107
Signature			Date
			November 12, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

CERTIFICATE OF MAILING - SEPARATE PAPER - PATENT APPLICATION

Attorney Docket No.: 674582-2001
Title : CYTOKINE ANTAGONIST MOLECULES
Filed : Herewith
Applicants : Andrew Robert Davids et al.

Mailed: **November 12, 2003** via "Express Mail Label # **EV345012744US**

I hereby certify that the Patent Application for the above-referenced application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to:

MAIL STOP PATENT APPLICATION
Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Enclosed: Utility Patent Application (total 98 pages, specification pages 1-87, claims page 88-97, abstract page 98, figures pages 1-22 (Fig. 1, 1 contd., 2, 3, 4, 5, 5 contd., 6, 6 contd., 6 contd., 7, 8, 8 contd., 9, 9 contd., 10, 11, 12, 13A, 13B, 14A, 14B, 15A, 15B, 15C, 15D)
Utility Patent Application Transmittal
Fee Transmittal
Declaration and Power of Attorney (unsigned)
Check Number 29160 in the amount of \$1,796.00
Return Receipt Postcard

Charles Jackson
(Type/printed name of person mailing paper or fee)

Charles Jackson
Signature